AbCellera Biologics saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 77 to 81.
When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
AbCellera Biologics is not currently near a potential buying area. While it is a low-priced stock, it does trade an average volume of millions of shares each day. As the stock clears key moving averages, see if the stock goes on to form a clear chart pattern that could launch a new move in higher than current trade volume.
The company showed 0% earnings growth last quarter. Sales gains came in at 1,740%.
AbCellera Biologics holds the No. 52 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab ADR and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
YOU MAY ALSO LIKE:
Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith's Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders
IBD Digital: Get access to subscriber-only stock lists and market analysis. Plus, add the weekly print edition for your weekend prep.